IN2014DN10259A - - Google Patents

Info

Publication number
IN2014DN10259A
IN2014DN10259A IN10259DEN2014A IN2014DN10259A IN 2014DN10259 A IN2014DN10259 A IN 2014DN10259A IN 10259DEN2014 A IN10259DEN2014 A IN 10259DEN2014A IN 2014DN10259 A IN2014DN10259 A IN 2014DN10259A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Tihamer Orban
Original Assignee
Orban Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orban Biotech Llc filed Critical Orban Biotech Llc
Publication of IN2014DN10259A publication Critical patent/IN2014DN10259A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN10259DEN2014 2012-05-24 2014-12-02 IN2014DN10259A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651144P 2012-05-24 2012-05-24
PCT/US2013/042627 WO2013177505A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers

Publications (1)

Publication Number Publication Date
IN2014DN10259A true IN2014DN10259A (enExample) 2015-08-07

Family

ID=49621783

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10259DEN2014 IN2014DN10259A (enExample) 2012-05-24 2014-12-02

Country Status (13)

Country Link
US (5) US20130316375A1 (enExample)
EP (2) EP2856149B1 (enExample)
JP (5) JP6312332B2 (enExample)
KR (1) KR102172285B1 (enExample)
CN (1) CN104520707B (enExample)
AU (4) AU2013266145A1 (enExample)
CA (1) CA2874507A1 (enExample)
DK (1) DK2856149T3 (enExample)
ES (1) ES2810227T3 (enExample)
IN (1) IN2014DN10259A (enExample)
MX (1) MX357169B (enExample)
WO (1) WO2013177505A1 (enExample)
ZA (1) ZA201409006B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN107003315B (zh) * 2014-12-25 2018-09-25 株式会社日立制作所 胰岛素分泌能力分析装置、具备该装置的胰岛素分泌能力分析系统以及胰岛素分泌能力分析方法
CN105567851A (zh) * 2016-02-29 2016-05-11 北京泱深生物信息技术有限公司 一种与糖尿病相关的分子标志物
EP3433612B1 (en) * 2016-03-22 2024-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
JP7852926B2 (ja) 2020-06-26 2026-04-28 ファイム ファーマ リミテッド 乾癬及び他の自己免疫疾患抗原免疫モジュレータ(aim)治療プラットフォーム
WO2022264088A1 (en) 2021-06-17 2022-12-22 Phaim Pharma Ltd. Individualized cell therapy using patient-derived antigen-specific regulatory t cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246212A1 (en) * 2005-09-30 2009-10-01 Kyoto University Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
JP7618502B2 (ja) * 2021-05-14 2025-01-21 東京計器株式会社 船舶用自動操舵装置

Also Published As

Publication number Publication date
EP3767295A1 (en) 2021-01-20
JP6312332B2 (ja) 2018-04-18
ZA201409006B (en) 2016-07-27
JP2023011814A (ja) 2023-01-24
AU2013266145A1 (en) 2015-01-15
US20190137483A1 (en) 2019-05-09
AU2023222980A1 (en) 2023-09-21
DK2856149T3 (da) 2020-08-17
KR102172285B1 (ko) 2020-11-02
US20250237643A1 (en) 2025-07-24
JP2018116061A (ja) 2018-07-26
JP2021001899A (ja) 2021-01-07
CN104520707B (zh) 2018-03-27
AU2019200824A1 (en) 2019-04-04
US20230333094A1 (en) 2023-10-19
EP2856149A1 (en) 2015-04-08
AU2019200824B2 (en) 2021-06-24
CA2874507A1 (en) 2013-11-28
ES2810227T3 (es) 2021-03-08
JP2024150702A (ja) 2024-10-23
US20160299128A1 (en) 2016-10-13
MX2014014348A (es) 2015-06-05
CN104520707A (zh) 2015-04-15
US20130316375A1 (en) 2013-11-28
AU2021202609A1 (en) 2021-05-27
JP2015520378A (ja) 2015-07-16
EP2856149A4 (en) 2016-06-01
JP6761827B2 (ja) 2020-09-30
EP2856149B1 (en) 2020-07-08
WO2013177505A1 (en) 2013-11-28
KR20150022878A (ko) 2015-03-04
MX357169B (es) 2018-06-28

Similar Documents

Publication Publication Date Title
BR112014019985A2 (enExample)
BR112014017625A2 (enExample)
BR112014017659A2 (enExample)
BR112014019130A2 (enExample)
BR112014017607A2 (enExample)
BR112014017646A2 (enExample)
BR112014017638A2 (enExample)
AR092201A1 (enExample)
BR112013027865A2 (enExample)
BR112014017644A2 (enExample)
BR112014017634A2 (enExample)
BR112014017588A2 (enExample)
BR112014017647A2 (enExample)
BR112014013184A8 (enExample)
BR112014017618A2 (enExample)
BR112014017627A2 (enExample)
BR112014017623A2 (enExample)
BR112014017652A2 (enExample)
BR112014017630A2 (enExample)
BR112014017621A2 (enExample)
BR112014017631A2 (enExample)
BR112014020234A2 (enExample)
BR112014017671A2 (enExample)
BR112014017589A2 (enExample)
BR112014017600A2 (enExample)